Sanofi-Aventis has acquired Ascendis’ proprietary TransCon Linker and Hydrogel carrier technology, allowing drug compounds to be released into the body in a precise, time-controlled fashion.

The technology creates bonds between larger molecules, such as proteins including insulin, and a carrier, allowing for tailor-made release profiles. The patent for the technology will be transferred as per the agreement.

Under the terms of the agreement, Sanofi-Aventis will receive worldwide rights to develop, manufacture and commercialise products using the technology to treat diabetes and related disorders.

Ascendis will receive an undisclosed upfront payment as well as development, regulatory and commercial milestone payments.